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Acetylsalicylic acid and/or its metabolites are implicated to have various eﬀects on metabolism and, especially, on mitochondrial
function. These eﬀects include both inhibitory and stimulatory eﬀects. We investigated the eﬀect of both combined and separate
oral acetylsalicylic acid and acetaminophen administration at therapeutic doses on the urinary metabolite proﬁle of human
subjects. In this paper, we provided in vivo evidence, in human subjects, of a statistically signiﬁcantincrease in isobutyrylcarnitine
after the administration of a therapeutic dose of acetylsalicylic acid. We, therefore, propose an inhibitory eﬀect of acetylsalicylic
acid on the short-chain fatty acid metabolism, possibly at the level of isobutyryl-CoA dehydrogenase.
1.Introduction
The dehydrogenation of acyl-CoA intermediates in the
catabolism of fatty acids and branched-chain amino acids in
humansiscatalysedbythemitochondrial acyl-CoAdehydro-
genase enzymes [1, 2]. Several inherited defects in this group
of enzymes have been characterised. Defects in, or inhibition
of, isovaleryl-CoA dehydrogenase and 2-methylbutyryl-CoA
dehydrogenase result in the accumulation of C5-carnitine
species [3] whilst defects in, or inhibition of, short-chain
acyl-CoAdehydrogenase andisobutyryl-CoA dehydrogenase
result in the accumulation of C4-carnitine species [2]
(Figure 1).
In the human body, acetylsalicylic acid is hydrolysed to
salicylic acid, which is excreted in its conjugated form with
glycine and glucuronic acid, in its hydroxylated form as 2,5-
dihydroxybenzoic acid, or unchanged as salicylic acid [4].
Numerous in vitro and in vivo studies have been conducted
that demonstrated various eﬀects of acetylsalicylic acid
(and its metabolites) on the metabolism and, especially, on
mitochondrial function, such as the uncoupling of oxidative
phosphorylation [5, 6], inhibition of fatty acid oxidation [5–
8] with the concomitant stimulation of cytochrome P450
dependent ω-oxidation [9], and, therefore, accumulation of
dicarboxylic acids [10]. In addition, the inhibition of both
the Krebs cycle enzymes α-ketoglutarate dehydrogenase, and
succinate dehydrogenase [6, 11], as well as an increased
ﬂux through the Krebs cycle [12], have been reported.
Other eﬀects of salicylic acid include the stimulation of
oxygen consumption, stimulation of ATP hydrolysis [5], the
activation of pyruvate dehydrogenase, and the inhibition of
gluconeogenesis [12]. It can also lead to decreased blood
glucose concentrations, increased hepatic triglycerides [6],
and a slight increase in (iso)butyryl-CoA, β-methylcrotonyl-
CoA, isovaleryl-CoA, and octanoyl-CoA concentrations
[13].
The exact mechanism of inhibition that acetylsalicylic
acidand/oritsmetabolitesexertonfattyacidoxidationisnot
clear, since diﬀerent studies indicate diﬀerent sites of inhi-
bition. These include an inhibitory eﬀect on the activation2 ISRN Pharmacology
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Figure 1: Proposed inhibition by salicylic acid of the branched-
chain amino acid catabolism. Inhibition (or deﬁciency) of (1)
isovaleryl-CoA dehydrogenase, (2) 2-methylbutyryl-CoA dehydro-
genase, and (3) isobutyryl-CoA dehydrogenase, will result in the
accumulation of C4-carnitine and C5-carnitine species.
and transportation of medium- and long-chain fatty acids
into the mitochondria [7], due to the sequestration of
extramitochondrial coenzymeAandcarnitine[6],inhibition
of the medium-chain acyl-CoA synthetase [8], or inhibition
of the carnitine acyltransferase (CAT) enzymes [14]. Con-
versely, it was demonstrated that the target of inhibition was
found to be at the level of the long-chain 3-hydroxyacyl-
CoA dehydrogenase (LCHAD) activity of the mitochondrial
trifunctional β-oxidation enzyme (MTE) and not at the level
of uptake or activation of fatty acids [15].
While performing biotransformation metabolism and
oxidative stress status proﬁling studies, on individuals
referred to our laboratory, by using acetylsalicylic acid and
acetaminophen as probe substrates, we made the rather
startling observation of the presence of elevated C3-, C4-,
and C5-carnitine species in their urine. These observations
led to a more in-depth investigation into the nature of
these acylcarnitine species and whether their increased
excretion was due to the separate or combined eﬀect of
the acetylsalicylic acid and acetaminophen administration.
Since the accumulation of C4- and C5-carnitine species
is predominantly associated with deﬁcient branched-chain
amino acid metabolism at the level of diﬀerent acyl-CoA
dehydrogenase enzymes [2, 3], we hypothesized that acetyl-
salicylic acid administration is associated with the elevation
of these species, which may be linked to the inhibition
of the metabolism of C4 and C5 fatty acids (Figure 1).
The formulation of this hypothesis was supported by the
previous observation that a slight increase in (iso)butyryl-
CoA, β-methylcrotonyl-CoA, isovaleryl-CoA, and octanoyl-
CoA concentrations occur after acetylsalicylic acid intake
[13].
This investigation provides the ﬁrst evidence of a sig-
niﬁcant increase in isobutyrylcarnitine excretion following
acetylsalicylic acid intake at therapeutic doses in humans,
and we propose that this accumulation may be due to
the inhibitory eﬀect of acetylsalicylic on the metabolism of
C4 and C5 fatty acids.
2.Materialsand Methods
2.1. Subjects. The test subjects were divided into two groups.
The ﬁrst group included 30 test subjects, 19 female and 11
male between the ages of 12 and 65 years. Participants in
this group were originally referred for biotransformation
metabolism and oxidative stress status assessment, which
include the administration of both acetaminophen and
acetylsalicylic acid. The second group included seven ran-
domly chosen participants from the ﬁrst group and were
used to ascertain whether the observed eﬀects were due
to acetylsalicylic acid intake, acetaminophen intake, or a
combination thereof. The study adhered to the guidelines
set in the Declaration of Helsinki. Approval for this work
was obtained from the Ethics Committee of the North-
West University, and informed consent was obtained from
all participating subjects.
2.2. Loading Protocol and Sample Collection. Fasting baseline
urine samples of all the test subjects in the ﬁrst test
group were collected the morning of the test day. At 21:00,
on the same day, all the test subjects ceased eating and
drinking (except water), emptied their bladders, and took
therapeutic doses (1000mg) acetaminophen and (600mg)
acetylsalicylic acid, as recommended by the diﬀerent phar-
maceutical companies for the relieve of mild to moderate
pain. The total volume of urine excreted for ten hours
after administration of acetaminophen and acetylsalicylic
acid was collected and the quantity of urine excreted was
documented.
The second test group followed a protocol to determine
if the observed eﬀect on the acylcarnitine proﬁle was due
to acetylsalicylic acid intake, acetaminophen intake, or a
combination thereof. On the ﬁrst day at 21:00, all subjects
ceased eating and drinking (except water) for the day and
collected a baseline urine sample, after which they emptied
their bladders. All subjects took 600mg of acetylsalicylic
acid and collected all the overnight urine until 7:00 the
next morning. On the second occasion, the same protocol
was followed except that all the subjects took 1000mg of
acetaminophen and collected all the overnight urine until
7:00 the next morning and on the third occasion all the
subjects took both 600mg acetylsalicylic acid and 1000mg
acetaminophen and collected all the overnight urine until
7:00 the next morning. Subjects waited for a minimum of
three days before going on to the next protocol.
2.3. Reagents. The following reagents were purchased from
Merck Chemical Co. (Darmstadt, Germany) acetonitrile,
formic acid, and methanol. 3N butanolic HCl, valine,
leucine, isoleucine, phenylalanine, methionine, citrulline,
glycine, and lysine were purchased from Sigma-Aldrich Co.
(St. Louis, USA). The following carnitine and acylcarni-
tine standards and deuterated carnitine and acylcarni-
tine standards were obtained from Dr. H. J. ten Brink,ISRN Pharmacology 3
Free University Hospital (Amsterdam, The Netherlands):
L-carnitine·HCl, acetyl-L-carnitine·HCl, propionyl-L-car-
nitine·HCl, isovaleryl-L-carnitine·HCl, octanoyl-L-carni-
tine·HCl, hexadecanoyl-L-carnitine·HCl, [methyl-d3]-L-
carnitine·HCl, [d3]-acetyl-L-carnitine·HCl, [3,3,3-d3]-pro-
pionyl-L-carnitine·HCl,[d9]-isovaleryl-L-carnitine·HCl, [8,
8,8-d3]-octanoyl-L-carnitine·HCl, and [16,16,16-d3]-hex-
adecanoyl-L-carnitine·HCl. The following deuteratedamino
acids were obtained from Cambridge Isotope Laboratories
Inc. (Andover, MA, USA): [d10]-L-isoleucine, [d8]-L-valine,
[d2]-glycine, [d3]-methyl-L-methionine, [d5]-ring-L-phe-
nylalanine, [d5]-L-glutamine, [d5]-indole-L-tryptophan, [d4]-
L-lysine:2HCl, and [d4]-L-citulline.
2.4. Electrospray Ionisation Tandem Mass Spectrometric (ESI-
MS/MS) Analysis of Acylcarnitines. The electrospray ion-
isation tandem mass spectrometry (ESI-MS/MS) method
for determination of serum acylcarnitines as described by
Vreken et al. [16] was adapted to determine acylcarnitines
in urine. To a microcentrifuge tube, 10μL centrifuged urine
was added to 400μL of the deuterated acylcarnitines (inter-
nal standard solution) with the following concentrations:
30.45μmol/Lfor[methyl-d3]-L-carnitine·HCl,20.83μmol/L
for [d3]acetyl-L-carnitine·HCl, 19.69μmol/L for [3,3,3-
d3]propionyl-L-carnitine·HCl, 17.73μmol/L for [d9]iso-
valeryl-L-carnitine·HCl, 15.43μmol/L for [8,8,8-d3]octan-
oyl-L-carnitine·HCl,and11.47μmol/Lfor[16,16,16-d3]hex-
adecanoyl-L-carnitine·HCl. The samples were then evapo-
rated to dryness under a gentle stream of nitrogen at 55◦C.
Tothedriedresidue,200μL3NbutanolicHClwasaddedand
thesampleswereincubatedat55◦Cfor20min.Thebutylated
samples were evaporated to dryness again under a stream
of nitrogen at 55◦C. The dried residue was reconstituted
in water:acetonitrile (50:50) (v/v) containing 0.1% formic
acid.
An Agilent 1200 series liquid chromatograph (Santa
Clara, CA, USA) with a 96-well plate sampler was used for
sample handling as well as mobile phase delivery. Samples
(10μL of each) were injected, and a constant ﬂow rate
of 0.2mL/min was maintained throughout the run. The
mobile phase consisted of 0.1% formic acid in water:ac-
etonitrile (50:50) (v/v). The tandem mass spectrometry
(MS/MS) analysis was performed on an Agilent 6410 Triple
Quadrupole (Santa Clara, CA, USA) in positive ionisation.
Acylcarnitines were analysed with a precursor ion scan, after
controlled collision induced dissociation, with a fragmentor
voltage of 135V and collision energy of 20V. All carnitine,
acylcarnitine, and other butylated species that yielded a
charged mass of 85Da after fragmentation were detected.
Acylcarnitines were quantiﬁed by comparison of the signal
intensity of carnitine and acylcarnitines against the signal
intensity of the corresponding deuterated analogues. The
concentrations of analysed carnitine and acylcarnitines were
expressed as mmol/mol creatinine.
2.5. Liquid Chromatography Tandem Mass Spectrometric (LC-
MS/MS) Analysis of Acylcarnitine Isomers. The LC-MS/MS
method for the separation and identiﬁcation of short-chain
acylcarnitine isomers as described by Ferrer et al. [17]w a s
used, with minor modiﬁcations to separate butyrylcarnitine
and isobutyrylcarnitine. A 100-μL volume of urine was
prepared the same as for the ESI-MS/MS method. High-
performance liquid chromatography was performed on an
Agilent 1200 series liquid chromatograph equipped with
a Luna C18(2) column (150mm × 2.00mm, particle size
5μm)fromPhenomenex(Torrance,CA,USA).Mobilephase
A consisted of 10mM ammonium acetate in water and
mobile phase B of 10mM ammonium acetate in methanol.
Column temperature was maintained at 20◦Ca n dt h eﬂ o w
rate at 0.2mL/min. The samples (10μL) were injected and
the mobile phase composition was changed from 40% of B
to 60% of B over 15min, after which the percentage of B was
further increased to 100% over the next 5min and kept for
5min. The percentage of B was changed back to 40% over
3min, and the column re-equilibrated for 7min.
The MS/MS analysis was performed on an Agilent 6410
Triple Quadrupole (Santa Clara, CA, USA) in positive
ionisation after controlled collision induced dissociation,
with optimised fragmentor voltages and collision energies
for butyrylcarnitine, isobutyrylcarnitine, and the deuter-
ated analogues used for quantiﬁcation. Mass spectrometry
conditions were optimised with the MassHunter optimiser
software from Agilent. Acylcarnitines were analysed in
multiple reaction monitoring (MRM) mode, with the fol-
lowing transitions being monitored, m/z 288 → 85 for
both butyrylcarnitine and isobutyrylcarnitine, m/z 277 →
85 for [3,3,3-d3]propionyl-L-carnitine·HCl, m/z 311 → 85
for [d9]isovaleryl-L-carnitine·HCl and m/z 347 →to 85
for [8,8,8-d3]octanoyl-L-carnitine·HCl. The concentrations
of C4-carnitine isomers were determined by comparing
the signal intensity of acylcarnitines against the signal
intensity of the corresponding deuterated analogues. For
both butyrylcarnitine and isobutyrylcarnitine, a linear rela-
tionship between concentration and intensity existed, with
R2 > 0.99. The concentrations of analysed acylcarnitine
isomers were expressed as mmol/mol creatinine.
2.6. Electrospray Ionisation Tandem Mass Spectrometric (ESI-
MS/MS) Analysis of Amino Acids. Samples were prepared
in the same way as for the analysis of acylcarnitines. Added
internal standard solution contained deuterated amino
acids with the following concentrations: 17.43μmol/L
for [d10]-L-isoleucine, 32.20μmol/L for [d8]-L-valine,
15.99μmol/L for [d2]-glycine, 3.98μmol/L for [d3]-methyl-
L-methionine, 5.77μmol/L for [d5]-ring-L-phenylalanine,
3.28μmol/L for [d5]-L-glutamine, 14.89μmol/L for [d5]-
indole-L-tryptophan, 14.16μmol/L for [d4]-L-lysine:2HCl,
and 4.21μmol/L for [d4]-L-citrulline.
Amino acids were analysed in MRM mode for the
following transitions: glycine m/z 132 → 30, [d2]-glycine
m/z 134 → 32, alanine m/z 146 → 44, serine m/z 162
→ 60, proline and arginine m/z 172 → 70, valine m/z
174 → 72, [d8]-L-valine, threonine m/z 176 → 74, leucine
and isoleucine m/z 188 →86, [d10]-L-isoleucine m/z 191 →
89, methionine m/z 206 → 104, [d3]-methyl-L-methionine
m/z 209 → 107, histidine m/z 212 to 110, citrulline4 ISRN Pharmacology
m/z 215 → 113, phenylalanine m/z 222 → 120, [d5]-ring-
L-phenylalanine m/z 227 → 125, tyrosine m/z 238 → 136,
aspartic acid m/z 246 → 144, glutamic acid m/z 260 →
158, glutamic acid-d3 m/z 263 → 161, tryptophan m/z 261
→ 159, [d5]-indole-L-tryptophan m/z 266 → 164, lysine
m/z 203 → 84, and [d4]-L-lysine:2HCl m/z 207 → 88.
The concentrations of the amino acids were determined by
comparing the signal intensity of the amino acids against the
signal intensity of the corresponding deuterated analogues.
The concentrations of analysed amino acids were expressed
as mmol/mol creatinine.
2.7. Liquid Chromatography Tandem Mass Spectrometric (LC-
MS/MS) Analysis of Branched-chain Amino Acids. Samples
were prepared in the same manner as for the determi-
nation of acylcarnitine isomers. High-performance liquid
chromatography was performed on an Agilent 1200 series
liquid chromatograph equipped with a Luna C18(2) column
(150mm × 2.00mm, particle size 5μm) from Phenomenex
(Torrance, CA, USA). Column temperature was maintained
at 20◦C, and the ﬂow rate at 0.2mL/min. Mobile phase A
consisted of 0.1% formic acid in water, and mobile phase B
of 0.1% formic acid in methanol. The samples (10μL) were
injected, and the mobile phase composition was changed
from 40% of B to 60% of B over 15min, after which the
percentage of B was further increased to 100% over the next
5min and kept for 5min. The percentage of B was changed
back to 40% over 3min, and the column re-equilibrated for
4min. The MS/MS analysis was performed on an Agilent
6410 Triple Quadrupole (Santa Clara, CA, USA) in positive
ionisation after controlled collision induced dissociation
with optimised fragmentor voltages and collision energies
for leucine, isoleucine, valine, and the deuterated analogues
used for quantiﬁcation. Mass spectrometry conditions were
optimised with the MassHunter optimiser software from
Agilent.Branched-chain amino acids were analysed in MRM
m o d e ,f o rt h es a m et r a n s i t i o n sa sd e s c r i b e di nt h eE S I -
MS/MS analysis of amino acids. The concentrations of the
branched-chain amino acids were determined by comparing
the signal intensity of the branched-chain amino acids
against the signal intensity of the corresponding deuter-
ated analogues. The concentrations of analysed branched-
chain amino acids were expressed as mmol/mol creati-
nine.
2.8. Statistical Analysis. Ap a i r e dt-test was used to demon-
strate statistically signiﬁcant diﬀerences between the test
samples. In all cases, statistical signiﬁcance was set at P<. 05.
3.Results
3.1. Acylcarnitine Analysis (ESI-MS/MS). Ac o m p a r i s o n
between the acylcarnitine proﬁles in baseline urine samples
of the ﬁrst test group (n = 30) obtained before and after
administration of a combination of acetylsalicylic acid and
acetaminophen, revealed a statistically signiﬁcant increase
in the excretion of C3- (P = .05), C4- (P = .00),
and C5-carnitine moieties (P = .00). Comparison of
the acylcarnitine proﬁles in baseline urine samples of the
second test group (n = 7) to the proﬁles obtained after
the administration of a therapeutic dose of acetylsalicylic
acid alone, revealed a statistically signiﬁcant increase in the
excretion of C4-carnitine (P = .03) (Table 1). However,
a comparison between the acylcarnitine proﬁles obtained
before and after the administration of a therapeutic dose of
acetaminophen (n = 7), revealed a decreased excretion of
various dicarboxylic acid carnitine conjugates, that is, C4-
DC (P = .05), C5-DC/C10-OH-carnitine (P = .01), C6-DC
(P = .01), and C8-DC (P = .00) (Table 1).
3.2. Acylcarnitine Isomer Analysis (LC-MS/MS). Comparing
the LC-MS/MS baseline data with that obtained after the
administration of a combination of acetylsalicylic acid and
acetaminophen, revealed that the increase in the excretion
of C4-carnitine was due to the increased excretion of
isobutyrylcarnitine (P = .04) rather than due to the increase
in butyrylcarnitine(P = .46)(Figure2).The resultsobtained
for the diﬀerent C4-carnitine isomers revealed no statisti-
cally signiﬁcant diﬀerence when either butyrylcarnitine or
isobutyrylcarnitine concentrations in baseline urine samples
were compared to samples (n = 7) taken after acetylsalicylic
acid administration (P = .61 and P = .20) and samples
(n = 7) taken after acetaminophen administration (P = .62
and P = .32).
3.3. Amino Acid Analysis (ESI-MS/MS & LC-MS/MS). Con-
cerning the amino acid analysis, a statistically signiﬁcant
decrease in the excretion of isoleucine (P = .00), leucine
(P = .04), valine (P = .01), and tryptophan (P =
.01) (Table 2) was evident in the urine samples obtained
after acetylsalicylic acid and acetaminophen administration
(n = 30). A comparison between the amino acid pro-
ﬁles in baseline urine samples and samples taken after
acetylsalicylic acid (n = 7) and acetaminophen (n = 7)
administration revealed a statistically signiﬁcant decrease in
the excretion of alanine, glycine, the branched-chain amino
acids, methionine, phenylalanine, tyrosine, lysine, histidine,
aspartic acid, and glutamic acid. In addition, signiﬁcantly
less proline/arginine, tryptophan, and serine were present in
the urine after acetaminophen administration, but not after
acetylsalicylic acid administration (Table 2).
4.Discussion
Acetylsalicylic acid and acetaminophen are generally used
as probe substrates in the evaluation of biotransformation
metabolism and oxidative stress status in humans [18].
Careful investigation of the acylcarnitine proﬁles of such
subjects revealed the presence of increased concentrations
of C3-, C4- and, C5-carnitine species in their urine. Since
these acylcarnitine species reached concentrations normally
associated with inborn errors of metabolism in some sub-
jects [19], it was investigated whether this phenomenon
originated from the administration of acetylsalicylic acid
or acetaminophen, or a combination thereof. An increased
excretion of various acylcarnitines derived from inhibitedISRN Pharmacology 5
Table 1: Paired t-test values (P-values) of acylcarnitine species in baseline urine samples compared to acylcarnitine species in urine samples
obtained after acetylsalicylic acid administration (n = 7), acetaminophen administration (n = 7), and combined administration of both
acetylsalicylic acid and acetaminophen (n = 30).
Acylcarnitine species
Paired t-test (P-value)
Acetylsalicylic acid
administration(n = 7)
Acetaminophen administration
(n = 7)
Combined administration
(n = 30)
C0-carnitine 0.18 0.20 0.72
C2-carnitine 0.08 0.06 0.87
C3-carnitine 0.96 0.88 0.05∗
C4-carnitine 0.03∗ 0.31 0.00∗
C4-OH-carnitine 0.18 0.12 0.32
C4-DC-carnitine 0.16 0.05∗ 0.08
C5-carnitine 0.73 0.85 0.00∗
C5-OH-carnitine 0.69 0.33 0.35
C5-DC/C10-OH-carnitine 0.17 0.01∗ 0.26
C5:1-carnitine 0.24 0.50 0.29
C6-carnitine 0.20 0.62 0.98
C6-DC-carnitine 0.29 0.01∗ 0.77
C8-carnitine 0.41 0.10 0.20
C8-DC-carnitine 0.84 0.00∗ 0.55
C10-carnitine 0.20 0.11 0.20
C5: 1-DC/C10:1-OH-carnitine 0.82 0.10 0.90
C12-carnitine 0.20 0.11 0.15
C14-carnitine 0.41 0.20 0.70
C16-carnitine 0.21 0.07 0.95
∗Diﬀerences are considered to be statisticallysigniﬁcant compared to baseline values if P<. 05.
Table 2: Paired t-test values (P-values) of amino acids in baseline urine samples compared to amino acids in urine samples obtained after
acetylsalicylic acid administration(n = 7),acetaminophenadministration(n = 7),and combinedadministrationofbothacetylsalicylic acid
and acetaminophen (n = 30).
Amino Acids
Paired t-test (P-value)
Acetylsalicylic acid
administration(n = 7)
Acetaminophen administration
(n = 7)
Combined administration
(n = 30)
Alanine 0.00∗ 0.00∗ 0.50
Glycine 0.03∗ 0.02∗ 0.82
Valine 0.02∗ 0.01∗ 0.01∗
Leucine 0.04∗ 0.03∗ 0.04∗
Isoleucine 0.02∗ 0.01∗ 0.00∗
Methionine 0.01∗ 0.01∗ 0.73
Proline/Arginine 0.06 0.02∗ 0.21
Phenylalanine 0.02∗ 0.01∗ 0.43
Tryptophan 0.12 0.03∗ 0.01∗
Serine 0.06 0.03∗ 0.32
Threonine 0.19 0.07 0.31
Tyrosine 0.01∗ 0.00∗ 0.13
Lysine 0.03∗ 0.03∗ 0.45
Histidine 0.01∗ 0.00∗ 0.20
Aspartic acid 0.05∗ 0.05∗ 1.00
Glutamic acid 0.02∗ 0.02∗ 0.39
∗Diﬀerences are considered to be statisticallysigniﬁcant compared to baseline values if P<. 05.6 ISRN Pharmacology
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Figure 2: Separation and identiﬁcation of short-chain acylcarnitine isomers. (a) In the LC-MS/MS analysis of acylcarnitine isomers,
isobutyrylcarnitine is detected at 17.282min and butyrylcarnitine at 18.042. (b) Product ion scan of m/z 288 for both isobutyrylcarnitine
and butyrylcarnitine.ISRN Pharmacology 7
fattyacidoxidation,suchasoctanoylcarnitineandpalmitoyl-
carnitine [7] as well as certain dicarboxylic acid carnitines
with chain lengths ranging from C6 to C12 [10]w e r e
expected after acetylsalicylic acid administration. In the case
of acetaminophen administration, an increased excretion of
palmitoylcarnitine was expected [20]. However, our analyses
revealed a statistically signiﬁcant increase in the excretion of
C4-carnitineinthecaseofacetylsalicylicacidadministration,
a statistically signiﬁcant decrease in the excretion of various
dicarboxylic acid carnitine conjugates after acetaminophen
administration, and a statistically signiﬁcant increase in the
excretion of C3-, C4-, and C5-carnitine in the case of the
combined administration. The most important observation
in this respect is that the increased excretion in C4-
carnitine was due to the intake of acetylsalicylic acid and not
acetaminophen or a combined eﬀect. Although there was no
statistically signiﬁcant diﬀerence in the C3- and C5-carnitine
concentrations after acetylsalicylic acid administration (n =
7),asin thecase ofthecombinedadministration, onecannot
exclude that acetylsalicylic acid could be the cause of this
increase,takingcognisanceoftherelativelysmall sample size.
It is known that butyrylcarnitine (C4-carnitine) accu-
mulates with deﬁcient or inhibited short-chain acyl-CoA
dehydrogenase and that isobutyrylcarnitine (C4-carnitine)
accumulates when isobutyryl-CoA dehydrogenase is deﬁ-
cientorinhibited[2].In thecaseofC5-carnitine, theisomers
include isovalerylcarnitine and 2-methylbutyrylcarnitine,
which will accumulate with deﬁcient or inhibited isovaleryl-
CoA dehydrogenase and 2-methylbutyryl-CoA dehydro-
genase [3]( F i g u r e1). It was demonstrated by Glasgow
et al. [15] that the metabolites of acetylsalicylic acid can
exercise mixed inhibition on β-oxidation at the level of
the LCHAD activity of the MTE, as a result of structural
similarities between acetylsalicylic acid and the acyl-part
of fatty acids. It was, therefore, necessary to determine
whether the observed increased excretion of C4-carnitine
was due to increased butyrylcarnitine or isobutyrylcarnitine.
The chromatographic separation of these isomers from each
other in both the baseline samples and the samples obtained
after acetylsalicylic acid and acetaminophen administration
was of utmost importance and during the chromatographic
separation, when performing a precursor ion scan for a
product with an m/z of 85, two precursor ions were detected
for C4-carnitine with an m/z of 288 (Figure 2).
A comparison of the amount of the C4-carnitine iso-
mers in the baseline samples to the test samples (after
acetylsalicylicacidandacetaminophenadministration, resp.)
revealed no statistically signiﬁcant diﬀerence. However, in
the samples analysed to investigate a possible combined
eﬀect of acetylsalicylic acid and acetaminophen admin-
istration (n = 30) a statistically signiﬁcant increase in
only the isobutyrylcarnitine concentration was observed.
These results support the hypothesis that acetylsalicylic
acid may have an inhibitory eﬀect on short-chain fatty
acid metabolism, possibly at the level of isobutyryl-CoA
dehydrogenase involved in the catabolism of branched-chain
amino acids. Since there was no observed eﬀect on these
metabolic pathways after acetaminophen administration
alone, the possibility also exists that the increase in C5-
carnitinespeciesobservedafterthecombinedadministration
may be due to the same inhibitory eﬀect on the short-
chain fatty acid metabolism. In this case, it can be at
the level of the isovaleryl-CoA dehydrogenase and S-2-
methylbutyryl-CoA dehydrogenase enzymes. Furthermore,
it has been demonstrated that methyl-enecyclopropylacetic
acid, a metabolite of hypoglycin can irreversibly inhibit all
three acyl-CoA dehydrogenase enzymes in the branched-
chain amino acid metabolism [21].
To further demonstrate the possible inhibitory eﬀect of
acetylsalicylic acid and/or its metabolites on the branched-
chain amino acid metabolism, the total amino acid proﬁles
were analysed. These analyses were also done on both base-
line samples and samples taken after acetylsalicylic acid and
acetaminophen administration, individually and combined.
The comparison between the amino acid proﬁles in baseline
urine samples and samples taken after acetylsalicylic acid
(n = 7) and acetaminophen (n = 7) administration
revealed a statistically signiﬁcant decrease in the excretion
of various amino acids, including the branched-chain amino
acids. While the combined administration of acetylsalicylic
acid and acetaminophen revealed a statistically signiﬁcant
decrease in only the branched-chain amino acids and
tryptophan. However, an increase in branched-chain amino
acid excretion after acetylsalicylic acid administration was
expected due to the proposed inhibitory eﬀect downstream
in the branched-chain amino acid catabolism.
In only some of the subjects, the amount of excreted
isobutyrylcarnitine after the administration of acetylsali-
cylic acid, reached concentrations normally associated with
isobutyryl-CoA dehydrogenase deﬁciency. In this regard, we
would like to speculate as to the possible implications of
this observation. Since not all individuals are aﬀected to
the same degree, it is possible that the inhibitory eﬀect of
acetylsalicylic acid is more pronounced in carriers of the
isobutyryl-CoA dehydrogenase deﬁciency or in individuals
with rate-limiting polymorphisms in the same enzyme
system. If this is indeed the case, it opens the opportunity
to investigate whether the administration of acetylsalicylic
acid can be used to predict the carrier status in isobutyryl-
CoA dehydrogenase deﬁciency. Since the ﬁrst patient with
isobutyryl-CoA dehydrogenase deﬁciency was diagnosed
only over a decade ago [21], and since there is substantial
variation in the clinical presentation of this deﬁciency, it
also poses the opportunity to investigate other biochemical
eﬀects involved in the pathology of deﬁcient isobutyryl-CoA
dehydrogenase, as the elucidation of the development of
phenotypic characteristics of metabolic diseases remains a
formidable challenge.
In conclusion, from the literature sources, it is clear that
acetylsalicylic acid and/or its metabolites have various eﬀects
on metabolism and, especially, on mitochondrial function.
In this study, the ﬁrst in vivo evidence, in human subjects,
of a statistically signiﬁcant increase in isobutyrylcarnitine
excretion as a result of the administration of a therapeutic
dose of acetylsalicylic acid was provided. Since it was previ-
ously demonstrated that the structural similarities between
acetylsalicylic acid and the acyl-portion of fatty acids can8 ISRN Pharmacology
result in mixed inhibition on β-oxidation [15], we propose a
possible inhibitory eﬀect on isobutyryl-CoA dehydrogenase,
as elevated isobutyrylcarnitine excretion is generally a result
ofa deﬁciencyin the branched-chain amino acid catabolism.
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